Microsoft Azure Growth Forecast Beats Expectations Amid Rising AI Competition 
Seagate Stock Surges After Strong Q3 Earnings Beat and Bullish Outlook 
Apple Q2 2026 Earnings Surge as iPhone 17 Sales Drive Record Revenue 
Robinhood Q1 Earnings Miss Expectations, Stock Drops After Hours 
GameStop Eyes eBay Acquisition as Stock Prices Surge After Hours 
Why Paycom Was Named a 2026 Platinum Employer on the Where You Work Matters List 
Starbucks Raises 2026 Outlook as Turnaround Strategy Boosts Sales and Earnings 
Ford Q1 Earnings Beat Expectations, Stock Surges on Strong Guidance 
Micro Systemation Reports Q1 Loss Amid Strategic Investments and Revenue Growth 
Berkshire Hathaway Q1 Earnings Jump 18% as Greg Abel Signals Disciplined Growth Strategy 
Air Liquide Q1 Revenue Misses Estimates Amid Currency and Energy Headwinds 
AstraZeneca Q1 2026 Earnings Surge on Strong Oncology and Rare Disease Drug Sales 
Amazon Stock Dips Despite Record Earnings as AI Infrastructure Spending Surges 
Coles Group Q3 Sales Rise Driven by Supermarkets and E-Commerce Growth 
Meta Raises 2026 Capex Outlook Amid AI Spending Surge, Shares Drop After Earnings 
Novartis Q1 2026 Earnings Miss Expectations as Generic Competition Pressures Sales 
Pershing Square Raises $5 Billion in Landmark U.S. IPO and Share Placement 
South Korean biopharmaceutical firm Celltrion Inc. will acquire the patent, trademark, and sales rights for 18 brands of Japan's Takeda Pharmaceutical in Asia-Pacific for 332.4 billion won.
The company will pursue the deal through its Singapore-based affiliate, hoping the complete the acquisition by year's end.
The nine markets covered by business rights include South Korea, Thailand, Malaysia, and Australia.
The 18 brands amassed a combined sales of $140 million in Asia-Pacific in 2018.
Celltrion plans to sell the brands through its affiliates Celltrion Pharma and Celltrion Healthcare.
The acquisition not only helps to stabilize the local supply of medication for hypertension, diabetes, and hyperlipidemia but also serves as Celltrion's first significant move in accelerating its push into the global market.
Celltrion had a net income of 298 billion won in 2019, a 17.5 percent surge from the year before.
